67259-63-6

Usage

Uses

Used in Pharmaceutical Industry:
Piperidine, 4-[4-(trifluoromethyl)phenyl]-, is used as a reactant in the preparation of N-arylheterocycles. These N-arylheterocycles are important as they serve as MCH (melanin-concentrating hormone) antagonists. MCH antagonists are of interest in the pharmaceutical field due to their potential role in treating various disorders, including obesity and depression, by modulating the activity of the MCH system in the brain.

InChI:InChI=1/C12H14F3N/c13-12(14,15)11-3-1-9(2-4-11)10-5-7-16-8-6-10/h1-4,10,16H,5-8H2

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 437998-30-6 1-t-Butoxycarbonyl-4-(4-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 220000-88-4 4-(4-trifluoromethyl-phenyl)-pyridine 
• 30459-17-7 1-[4-(trifluoromethyl)phenyl]piperazine 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 67259-64-7 1,2,3,6-tetrahydro-4-(α,α,α-trifluoro-p-tolyl)pyridine 

Downstream Products

• 1268862-81-2 3-(4-fluorophenyl)-2-(4-(4-(trifluoromethyl)phenyl)piperidin-1-yl)quinoxaline-6-carboxylic acid 
• 1268865-74-2 methyl 3-(4-fluorophenyl)-2-(4-(4-(trifluoromethyl)phenyl)piperidin-1-yl)quinoxaline-6-carboxylate 
• 1268865-26-4 methyl 2-phenyl-3-(4-(4-(trifluoromethyl)phenyl)piperidin-1-yl)quinoxaline-6-carboxylate 
• 1181965-76-3 ethyl 4-oxo-1-({4-[4-(trifluoroethyl)phenyl]piperidin-1-yl}methyl)-4H-quinolizine-3-carboxylate 
• 180157-76-0 (2S)-(-)-1-(4-indolyloxy)-3-(4-(4-trifluoromethylphenyl)piperidin-1-yl)-2-propanol ethanedioate 
• 721953-51-1 5,5-bis(4-fluorophenyl)-2-methyl-3-(3-oxo-3-{4-[4-(trifluoromethyl)phenyl]-1-piperidinyl}propyl)-3,5-dihydro-4H-imidazol-4-one 
• 1361316-84-8 1-(3-hydroxypropyl)-4-[4-(trifluoromethyl)phenyl]piperidine 
• 133229-05-7 1-(4-Nitro-phenoxy)-3-[4-(4-trifluoromethyl-phenyl)-piperidin-1-yl]-propan-2-ol 

Relevant academic research and scientific papers

PYRAZOLO[1,5-a]PYRIMIDIN-7(4H)-ONE INHIBITORS OF DYNEIN

Pyrazolo[1,5-a]pyrimidin-7(4H)-ones of formula (I) inhibit intraflagellar transport and are useful as anticancer agents and as probes of the function of dynein-dependent systems.

Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents

Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

SUBSTITUTED 3,5-DIHYDRO-4H-IMIDAZOL-4-ONES FOR THE TREATMENT OF OBESITY

This invention relates to substituted 3,5-dihydro-4H-imidazol-4-ones compounds which are useful in the treatment of obesity and obesity-related disorders, and as weight-loss and weight-control agents. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

1,2 DIAMIDO CYCLOALKYL SODIUM CHANNEL BLOCKERS

1,2 Diamido cycloalkyl compounds that are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidin-dione and aryl-link-aryl oxazolodine-dione compounds and a pharmaceutically acceptable carrier; and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as irritable bowel syndrome, Crohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar disease, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolodine-dione compounds, either alone, or in combination with one or more therapeutically active compounds, are described.

3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4fare defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.